Releasing and separating cells from surfaces and capture molecules are critical steps in cell therapy development. Research into such therapies as chimeric antigen receptor T cells (CAR-T) cancer therapies and stem-cell regenerative medicines demand the isolation and purification of viable and functional target cells. A number of cell-separation strategies can be used to produce such cells, but they are not able to deliver the required efficiency or scalability and can also cause damage to cells or affect their phenotype. CEO Sean Kevlahan is featured in an interview where he provides insight into cell separation challenges and potential benefits of incorporating QuickGel into this challenging workflow. This is also a good opportunity to learn about the downstream applications our MagCloudz research use customers in academia and government institutions are thinking about for future therapeutic and clinical use.